Sinusitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Sinusitis pipeline market report provides a comprehensive overview of the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.
Sinusitis Pipeline Drugs Market by Key Targets
In the Sinusitis pipeline drugs market, the key targets are Glucocorticoid Receptor, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, Thymic Stromal Lymphopoietin, Calcitonin Gene Related Peptide Type 1 Receptor, P Selectin, 23S Ribosomal RNA, 30S Ribosomal Subunit, Beta Lactamase, and C-C Chemokine Receptor Type 4.
Key Targets in the Sinusitis Pipeline Drugs Market
For more target insights, download a free report sample
Key MoA in the Sinusitis Pipeline Drugs Market
Glucocorticoid Receptor Agonist has the highest share in the Sinusitis pipeline drugs market. The other key mechanisms of action are Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, P Selectin Inhibitor, 23S Ribosomal RNA Inhibitor, 30S Ribosomal Subunit Inhibitor, Beta Lactamase Inhibitor, and C-C Chemokine Receptor Type 4 Antagonist.
Sinusitis Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Sinusitis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Sinusitis pipeline drug market are subcutaneous, nasal, intravenous, oral, ophthalmic, transmucosal, and topical. Subcutaneous has the maximum number of pipeline products.
Sinusitis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Sinusitis Pipeline Drugs Market
The key molecule types in the Sinusitis pipeline drugs market are small molecule, monoclonal antibody, biologic, peptide, and synthetic peptide. Small molecule has the maximum number of pipeline products.
Sinusitis Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Sinusitis Pipeline Drugs Market
Some of the major companies in the Sinusitis pipeline drugs market are GSK plc, KeyMed Biosciences Inc, Lyra Therapeutics Inc, Biohaven Pharmaceutical Holding Company Ltd, GlycoMira Therapeutics Inc, 3SBio Inc, Amgen Inc, Amytrx Therapeutics Inc, AnaptysBio Inc, Aodh Lifesciences Pvt Ltd, and Argenx SE.
Sinusitis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Sinusitis Pipeline Drugs Market Overview
Key Targets | Glucocorticoid Receptor, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, Thymic Stromal Lymphopoietin, Calcitonin Gene Related Peptide Type 1 Receptor, P Selectin, 23S Ribosomal RNA, 30S Ribosomal Subunit, Beta Lactamase, and C-C Chemokine Receptor Type 4 |
Key Mechanisms of Action | Glucocorticoid Receptor Agonist, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, P Selectin Inhibitor, 23S Ribosomal RNA Inhibitor, 30S Ribosomal Subunit Inhibitor, Beta Lactamase Inhibitor, and C-C Chemokine Receptor Type 4 Antagonist |
Key Routes of Administration | Subcutaneous, Nasal, Intravenous, Oral, Ophthalmic, Transmucosal, and Topical |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Biologic, Peptide, and Synthetic Peptide |
Major Companies | GSK plc, KeyMed Biosciences Inc, Lyra Therapeutics Inc, Biohaven Pharmaceutical Holding Company Ltd, GlycoMira Therapeutics Inc, 3SBio Inc, Amgen Inc, Amytrx Therapeutics Inc, AnaptysBio Inc, Aodh Lifesciences Pvt Ltd, and Argenx SE |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis
- The pipeline guide reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sinusitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sinusitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Sinusitis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sinusitis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Amgen Inc
Amytrx Therapeutics Inc
AnaptysBio Inc
Aodh Lifesciences Pvt Ltd
Argenx SE
Beijing FuKangren Bio-pharm Tech Co Ltd
Biohaven Pharmaceutical Holding Company Ltd
Furen Pharmaceutical Group Co Ltd
GeneOne Life Science Inc
Genrix (Shanghai) Biopharmaceutical Co Ltd
GlycoMira Therapeutics Inc
GSK plc
Insmed Inc
IVIEW Therapeutics Inc
Jantar GmbH
JiangSu Qyuns Therapeutics Co Ltd
KeyMed Biosciences Inc
Kyowa Kirin Co Ltd
Lanier Biotherapeutics Inc
Lyra Therapeutics Inc
Maxwell Biosciences Inc
Merck & Co Inc
Nexeos Bio
Nota Laboratories LLC
OptiNose Inc
Oticara Inc
Pfizer Inc
ProclaRx LLC
Quorum Innovations LLC
RAPT Therapeutics Inc
Recce Pharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
SaNOtize Research and Development Corp
Shandong Boan Biotechnology Co Ltd
Suzhou Connect Biopharmaceuticals Ltd
Synermore Biologics Co Ltd
Trellis Bioscience Inc
Wuhan Yicheng Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Sinusitis pipeline drug market?
In the Sinusitis pipeline drugs market the key targets are Glucocorticoid Receptor, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, Thymic Stromal Lymphopoietin, Calcitonin Gene Related Peptide Type 1 Receptor, P Selectin, 23S Ribosomal RNA, 30S Ribosomal Subunit, Beta Lactamase, and C-C Chemokine Receptor Type 4.
-
What are the key mechanisms of action in the Sinusitis pipeline drugs market?
In the Sinusitis pipeline drugs market the key mechanisms of action are Glucocorticoid Receptor Agonist, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, Thymic Stromal Lymphopoietin Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, P Selectin Inhibitor, 23S Ribosomal RNA Inhibitor, 30S Ribosomal Subunit Inhibitor, Beta Lactamase Inhibitor, and C-C Chemokine Receptor Type 4 Antagonist.
-
What are the key routes of administration in the Sinusitis pipeline drugs market?
The key routes of administration in the Sinusitis pipeline drug market Subcutaneous, Nasal, Intravenous, Oral, Ophthalmic, Transmucosal, and Topical. Subcutaneous has the maximum number of pipeline products.
-
What are the key molecule types in the Sinusitis pipeline drugs market?
The key molecule types in the Sinusitis pipeline drug market are Small Molecule, Monoclonal Antibody, Biologic, Peptide, and Synthetic Peptide.
-
What are the major companies in the Sinusitis pipeline drugs market?
In the Sinusitis pipeline drugs market the major companies are GSK plc, KeyMed Biosciences Inc, Lyra Therapeutics Inc, Biohaven Pharmaceutical Holding Company Ltd, GlycoMira Therapeutics Inc, 3SBio Inc, Amgen Inc, Amytrx Therapeutics Inc, AnaptysBio Inc, Aodh Lifesciences Pvt Ltd, and Argenx SE.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.